Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1900B||SWOG||A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LungMAP Sub-Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-LU005||NRG||Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab||Adult CIRB - Late Phase Emphasis||Available to Open|
|N0723||NCCTG||MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib||Adult CIRB - Late Phase Emphasis||Completed|
|EA2174||ECOG-ACRIN||A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|TRC-10446||NCI||Tocilizumab in Hospitalized Cancer Patients with Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A091605||Alliance||A Randomized Phase II Study of anti-PD1 antibody [MK-3475 (pembrolizumab)] alone versus anti- PD1 antibody plus Stereotactic Body Radiation therapy in advanced Merkel Cell Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|ABTC-1802||ABTC||A Phase II Study of Binimetinib in Combination with Encorafenib in Adults with Recurrent BRAF V600-Mutated High-Grade Astrocytoma or other Primary Brain Tumor||Adult CIRB - Late Phase Emphasis||Available to Open|
|E3F05||ECOG||Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0421||SWOG||Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-30801||CALGB||A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer||Adult CIRB - Late Phase Emphasis||Completed|